Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 04:30PM GMT
Release Date Price: €18.6 (+11.38%)
Yuko Oku
JP Morgan Chase & Co, Research Division - Analyst

Hi. I'm Yuko Oku, one of the associates on the biotech team at JPMorgan. It's a pleasure to welcome Denali to the JPMorgan Conference. A quick housekeeping note before we begin, we'll be holding a Q&A session right after the presentation in the Georgian room just across the hall.

With that, I'd like to turn it over to CEO, Ryan Watts.

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

All right. It's exciting to be here again at JPMorgan, especially exciting today because we're presenting new data. A little bit unusual, we're going to go into some depth. I love data, we love data. We're going to share some clinical data, plus progress in the portfolio. But I'd like to start with a reminder, which is the huge unmet need we're trying to tackle. We've seen incredible progress in oncology, rare disease, obviously, new modalities. Many of us, including myself, have worked in the oncology space, and now we're turning our attention to neurodegeneration. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot